Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 971

1.

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.

J Clin Invest. 1993 Jan;91(1):301-7.

PMID:
8423228
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.

Diabetes Care. 1996 Jun;19(6):580-6.

PMID:
8725855
[PubMed - indexed for MEDLINE]
3.

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.

Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B.

Diabetes. 2004 Mar;53(3):654-62.

PMID:
14988249
[PubMed - indexed for MEDLINE]
Free Article
4.

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.

Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK.

Regul Pept. 1994 Apr 14;51(1):63-74.

PMID:
8036284
[PubMed - indexed for MEDLINE]
5.

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Diabetologia. 2002 Aug;45(8):1111-9. Epub 2002 Jul 4.

PMID:
12189441
[PubMed - indexed for MEDLINE]
6.

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH.

Am J Physiol. 1997 Nov;273(5 Pt 1):E981-8.

PMID:
9374685
[PubMed - indexed for MEDLINE]
Free Article
7.

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Regul Pept. 2003 Jul 15;114(2-3):115-21.

PMID:
12832099
[PubMed - indexed for MEDLINE]
8.

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.

Nauck MA, El-Ouaghlidi A, Gabrys B, Hücking K, Holst JJ, Deacon CF, Gallwitz B, Schmidt WE, Meier JJ.

Regul Pept. 2004 Nov 15;122(3):209-17.

PMID:
15491793
[PubMed - indexed for MEDLINE]
9.

alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.

Hücking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, Nauck MA.

Diabet Med. 2005 Apr;22(4):470-6.

PMID:
15787675
[PubMed - indexed for MEDLINE]
10.

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ.

Diabetes. 2001 Mar;50(3):609-13.

PMID:
11246881
[PubMed - indexed for MEDLINE]
Free Article
11.

Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.

Meier JJ, Kemmeries G, Holst JJ, Nauck MA.

Diabetes. 2005 Jul;54(7):2212-8.

PMID:
15983224
[PubMed - indexed for MEDLINE]
Free Article
12.

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.

Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.

J Clin Endocrinol Metab. 2003 Oct;88(10):4897-903.

PMID:
14557471
[PubMed - indexed for MEDLINE]
13.

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W.

Diabet Med. 1998 Nov;15(11):937-45.

PMID:
9827848
[PubMed - indexed for MEDLINE]
14.

Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1).

Ranganath L, Schaper F, Gama R, Morgan L, Wright J, Teale D, Marks V.

Diabetes Metab Res Rev. 1999 Nov-Dec;15(6):390-4.

PMID:
10634963
[PubMed - indexed for MEDLINE]
15.

Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus.

Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Fanelli A, Messeri G, Rotella CM.

Diabet Med. 2000 Oct;17(10):713-9.

PMID:
11110504
[PubMed - indexed for MEDLINE]
16.
17.

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Højberg PV, Vilsbøll T, Rabøl R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S.

Diabetologia. 2009 Feb;52(2):199-207. doi: 10.1007/s00125-008-1195-5. Epub 2008 Nov 27.

PMID:
19037628
[PubMed - indexed for MEDLINE]
18.

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B.

Diabetologia. 1996 Dec;39(12):1546-53.

PMID:
8960841
[PubMed - indexed for MEDLINE]
19.

Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.

Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA.

Diabet Med. 1998 Jun;15(6):485-91.

PMID:
9632123
[PubMed - indexed for MEDLINE]
20.

Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy.

Fukase N, Manaka H, Sugiyama K, Takahashi H, Igarashi M, Daimon M, Yamatani K, Tominaga M, Sasaki H.

Acta Diabetol. 1995 Oct;32(3):165-9.

PMID:
8590785
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk